Thalia Therapeutics Overview
- Year Founded
-
1979
- Status
-
Public
- Employees
-
3
- Stock Symbol
-
THAT
- Investments
-
4
Thalia Therapeutics General Information
Description
Thalia Therapeutics PLC is a specialist pharmaceutical company engaged in the development of mesoparticulate silica delivery systems to improve the cellular delivery and potency of vaccines. The company engaged in the development of a Liptide platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The Group operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec and its liptide platform called ECP105.
Contact Information
Website
www.thaliatx.comCorporate Office
- Weston house
- 2 Portman Street
- London W1H 6DU
- England, United Kingdom
Corporate Office
- Weston house
- 2 Portman Street
- London W1H 6DU
- England, United Kingdom
Thalia Therapeutics Timeline
Thalia Therapeutics Stock Performance
As of 12-Nov-2026, Thalia Therapeutics’s current market cap is $13.6M with 1.78B shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.6M | 1.78B | 829K |
Thalia Therapeutics Financials Summary
As of 30-Jun-2026, Thalia Therapeutics has a trailing 12-month revenue of $9.7K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,740 | 3,559 | 1,125 | 1,267 |
| Revenue | 10 | 10 | 9 | 2 |
| EBITDA | (1,949) | (1,535) | (1,560) | (1,771) |
| Net Income | (1,961) | (1,587) | (1,353) | (1,578) |
| Total Assets | 3,586 | 1,573 | 973 | 1,625 |
Thalia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Thalia Therapeutics Comparisons
Industry
Financing
Details
Thalia Therapeutics Competitors (28)
One of Thalia Therapeutics’s 28 competitors is Biocon, a Formerly PE-Backed company based in Bengaluru, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| AbbVie | Corporation | North Chicago, IL | ||||
| Nevian Lifescience | Corporate Backed or Acquired | Dhaka, Bangladesh | ||||
| Roche | Corporation | Basel, Switzerland | ||||
| Cipla | Corporation | Mumbai, India |
Thalia Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Thalia Therapeutics Patents
Thalia Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026120280-A1 | Hollow mesoporous silica nanoparticles and a | Pending | 03-Dec-2024 | ||
| GB-202417694-D0 | Nanoparticles | Pending | 03-Dec-2024 | ||
| GB-202009561-D0 | Method of making nanoparticles | Inactive | 23-Jun-2020 | ||
| AU-2021258537-A1 | Transfection and transduction system | Inactive | 23-Apr-2020 | ||
| CA-3176053-A1 | Transfection and transduction system | Pending | 23-Apr-2020 | A61K47/6901 |
Thalia Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Thalia Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Thalia Therapeutics Investments & Acquisitions (4)
Thalia Therapeutics’s most recent deal was a Merger/Acquisition with Sanmirna Therapeutics for . The deal was made on 24-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sanmirna Therapeutics | 24-Jun-2026 | Merger/Acquisition | Drug Discovery | ||
| Sanmirna Therapeutics | 24-Jun-2026 | Early Stage VC | Drug Discovery | ||
| Nanogenics | 28-Sep-2023 | Merger/Acquisition | Drug Delivery | ||
| Onzima Ventures | 13-Apr-2017 | Merger/Acquisition | Other Financial Services |
Thalia Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Thalia Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sanmirna Therapeutics | Amsterdam, Netherlands |
Thalia Therapeutics FAQs
-
When was Thalia Therapeutics founded?
Thalia Therapeutics was founded in 1979.
-
Where is Thalia Therapeutics headquartered?
Thalia Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Thalia Therapeutics?
Thalia Therapeutics has 3 total employees.
-
What industry is Thalia Therapeutics in?
Thalia Therapeutics’s primary industry is Drug Discovery.
-
Is Thalia Therapeutics a private or public company?
Thalia Therapeutics is a Public company.
-
What is Thalia Therapeutics’s stock symbol?
The ticker symbol for Thalia Therapeutics is THAT.
-
What is the current market cap of Thalia Therapeutics?
The current market capitalization of Thalia Therapeutics is $13.6M.
-
What is Thalia Therapeutics’s current revenue?
The trailing twelve month revenue for Thalia Therapeutics is $9.7K.
-
Who are Thalia Therapeutics’s competitors?
Biocon, AbbVie, Nevian Lifescience, Roche, and Cipla are some of the 28 competitors of Thalia Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
